Anika Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Anika Therapeutics, Inc. (ANIK) reported Business Acquisition, Pro Forma Net Income (Loss) of $9.37 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-03-16
- Anika Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-06-30 was $6.53M.
- Anika Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-03-31 was $2.84M, a 58.20% decline year-over-year.
- Anika Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$15.66M.
- Anika Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-09-30 was -$6.41M, a 230.60% decline year-over-year.
- Anika Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$22.98M, a 421.72% decline from fiscal 2019.
- Anika Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2019 was $7.14M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2021-06-30 | $6.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $9.37M 10-Q · filed 2021-08-06 | -$6.29M derived: sum of 3 quarters · filed 2023-03-16 | -$12.70M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $2.84M 10-Q · filed 2021-05-07 | -$12.82M derived: sum of 2 quarters · filed 2023-03-16 | -$19.23M derived: sum of 3 quarters · filed 2023-03-16 | -$26.94M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | -$15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$22.07M derived: sum of 2 quarters · filed 2023-03-16 | -$29.77M derived: sum of 3 quarters · filed 2023-03-16 | -$22.98M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$6.41M 10-Q · filed 2020-11-05 | -$14.12M derived: sum of 2 quarters · filed 2020-11-05 | -$7.33M 10-Q · filed 2021-11-05 | -$7.48M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | -$7.71M 10-Q · filed 2020-08-07 | -$917.00K 10-Q · filed 2021-08-06 | -$1.07M derived: sum of 3 quarters · filed 2022-03-11 | $3.84M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $6.79M 10-Q · filed 2021-05-07 | $6.64M derived: sum of 2 quarters · filed 2022-03-11 | $11.55M derived: sum of 3 quarters · filed 2022-03-11 | $16.62M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | -$152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $4.76M derived: sum of 2 quarters · filed 2022-03-11 | $9.83M derived: sum of 3 quarters · filed 2022-03-11 | $7.14M 10-K · filed 2022-03-11 |
| 2019-09-30 | $4.91M 10-Q · filed 2020-11-05 | $9.98M derived: sum of 2 quarters · filed 2020-11-05 | $7.30M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $5.07M 10-Q · filed 2020-08-07 | $2.39M 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |